Schering Plough begins acadesine enrolment

Pharmaceutical Company Product News

Schering-Plough has begun the enrolment process for a study focused on acadesine.

Acadesine is being investigated as a possible treatment via intravenous infusion to prevent ischemia-reperfusion injury. This is a complication sometimes experienced by people undergoing coronary artery bypass graft surgery with a cardiopulmonary bypass procedure.

The company said it has started to recruit subjects for the phase III RED-CABG trial, after having licensed the drug from privately-held pharmaceutical company PeriCor Therapeutics.

Complication rates from the aforementioned operations are "unacceptably high", it added.

"Schering-Plough is committed to addressing the significant unmet medical need in ischemia-reperfusion injury in this patient population," remarked Dr Enrico Veltri, group vice-president of global clinical research, cardiovascular and metabolic diseases at the Schering-Plough Research Institute.

Meanwhile, the end of last month saw the company release final results from its three large Pegintron (peginterferon alfa-2b) clinical studies for the treatment of hepatitis C.

They were presented at the 44th European Association for the Study of the Liver.

See all the latest jobs in Pharmaceutical
Return to news